Communications Biology · 2021 · 24 citations · 50 references
Life SciencesImmunologyOncologyCancer ImmunologyImmunotherapyTumor ImmunologyAntitumor T Cell ResponsesCancer ImmunotherapyCombination ImmunotherapyImmunotherapy For Solid TumorsTumor AntigensTumor-associated AntigensAdaptive Immune Response PrimingDruggable Target DiscoveryImmunogenicity Of Tumor AntigensMhc Class I MoleculesPeptide EpitopesSynergistic Immunotherapy MechanismsTumor Antigen ImmunogenicityTumor Antigen-based Immunotherapy
Abstract The success of cancer immunotherapy relies on the induction of an immunoprotective response targeting tumor antigens (TAs) presented on MHC-I molecules. We demonstrated that the splicing inhibitor isoginkgetin and its water-soluble and non-toxic derivative IP2 act at the production stage of the pioneer translation products (PTPs). We showed that IP2 increases PTP-derived antigen presentation in cancer cells in vitro and impairs tumor growth in vivo. IP2 action is long-lasting and dependent on the CD8 + T cell response against TAs. We observed that the antigen repertoire displayed on MHC-I molecules at the surface of MCA205 fibrosarcoma is modified upon treatment with IP2. In particular, IP2 enhances the presentation of an exon-derived epitope from the tumor suppressor nischarin. The combination of IP2 with a peptide vaccine targeting the nischarin-derived epitope showed a synergistic antitumor effect in vivo. These findings identify the spliceosome as a druggable target for the development of epitope-based immunotherapies.
50
Frank Dieterle, Alfred Ross, Götz Schlotterbeck et al. · Analytical Chemistry · 2006 · 1.8K citations
Properties of MHC Class I Presented Peptides That Enhance Immunogenicity
Jorg J. A. Calis, Matt Maybeno, Jason Greenbaum et al. · PLoS Computational Biology · 2013 · 936 citations · Full text